Drug Trial Radar · NCT05056974
A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs
Last checked: Nov 19, 2026Latest source record: Feb 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
11
Actual
Start
Dec 2, 2021
Primary completion
Feb 1, 2023
Study completion Feb 1, 2023
Sponsor
- Lead sponsor
- United BioPharmaIndustry
- Sponsor type
- Industry
- First posted
- Sep 27, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase II proof-of-concept trial study to assess the safety and efficacy of UB-421 monotherapy plus chidamide in changing the latent HIV reservoir among ART-treated HIV-1 adults with stably viral suppression who undergo ART interruption.
Conditions
- HIV-1 Infection
Interventions
UB-421Biological
10 mg/kg, weekly UB-421 during the 8-week
chidamideDrug
10 mg/dose, twice a week for 8 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- HIV cell-associated RNA levelsTime frame: Post-treatment weeks up to 48 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kaohsiung Veterans General Hospital
Kaohsiung City, Taiwan, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.